Application of Bupivacaine Liposome Iliofascial Space Block in Patients Undergoing Total Hip Replacement

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500109789

Enrollment

Unknown

Registered

2025-09-25

Start date

2025-09-25

Completion date

Unknown

Last updated

2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hip fracture

Interventions

Test group:Liposomal bupivacaine ultrasound-guided iliac fascia block+lumbar epidural anesthesia

Control group:Ropivacaine iliac fascial block+lumbar epidural anesthesia

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients aged >= 18 years who choose ASAI - III for elective total hip arthroplasty

Exclusion criteria

Exclusion criteria: Neurological diseases, cognitive impairment, severe hypertension, uncontrolled heart disease, and liver and kidney dysfunction were not included in the study.

Design outcomes

Primary

Measure	Time frame
Evaluation of Postoperative Analgesia;Evaluation of muscle strength after operation;	—

Secondary

Measure	Time frame
Postoperative inflammatory factor levels;Postoperative analgesic drug consumption;	—

Countries

China

Contacts

Public ContactZhang Ting

Enshi City Center Hospital

Zhangting9129@163.com+86 186 7169 0295

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026